11,058 Shares in Revolution Medicines, Inc. $RVMD Purchased by Rakuten Investment Management Inc.

Key Points

• Rakuten Investment Management initiated a Revolution Medicines position, acquiring 11,058 shares worth approximately $2.26 million in the third quarter. Institutional investors collectively own 94.34% of the stock.
• Revolution Medicines reported third-quarter revenue of $197.6 million, far above the $25.6 million consensus, with Rasonque generating that revenue in its first five weeks in the U.S.; its loss per share was also narrower than expected.
• Analysts have raised several price targets, while company insiders sold nearly 291,000 shares worth about $59.4 million over the past three months.

Rakuten Investment Management Inc. acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,058 shares of the company's stock, valued at approximately $2,261,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Alphabet Inc. bought a new stake in Revolution Medicines during the second quarter worth $551,843,000. Assenagon Asset Management S.A. increased its stake in shares of Revolution Medicines by 987.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company's stock valued at $447,710,000 after purchasing an additional 1,980,699 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Revolution Medicines in the 2nd quarter valued at $184,267,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Revolution Medicines by 82.3% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company's stock worth $170,862,000 after buying an additional 411,740 shares in the last quarter. Finally, Deutsche Bank AG acquired a new position in shares of Revolution Medicines during the 2nd quarter worth $166,308,000. 94.34% of the stock is currently owned by institutional investors.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Mark Goldsmith sold 80,000 shares of the company's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the transaction, the insider owned 267,330 shares in the company, valued at $55,925,436. This represents a 23.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alan Sandler sold 6,309 shares of the firm's stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $202.14, for a total value of $1,275,301.26. Following the sale, the insider directly owned 52,559 shares of the company's stock, valued at approximately $10,624,276.26. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 290,991 shares of company stock worth $59,422,765. Company insiders own 7.60% of the company's stock.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $192.28 on Friday. The company has a market cap of $41.21 billion, a price-to-earnings ratio of -21.11 and a beta of 1.44. Revolution Medicines, Inc. has a 52 week low of $58.91 and a 52 week high of $224.31. The company has a quick ratio of 11.38, a current ratio of 8.36 and a debt-to-equity ratio of 0.44. The firm has a 50 day moving average of $196.88 and a 200-day moving average of $157.56.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, beating analysts' consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million for the quarter, compared to analysts' expectations of $25.58 million. During the same period in the previous year, the business posted ($1.61) earnings per share. On average, equities analysts forecast that Revolution Medicines, Inc. will post -7.88 earnings per share for the current year.

Analysts Set New Price Targets

RVMD has been the subject of several recent analyst reports. Brookline Capital Markets assumed coverage on Revolution Medicines in a research report on Monday, September 28th. They set a "buy" rating and a $318.00 price objective for the company. UBS Group lifted their target price on Revolution Medicines from $220.00 to $265.00 and gave the company a "buy" rating in a research report on Friday, August 28th. Guggenheim boosted their target price on Revolution Medicines from $275.00 to $298.00 and gave the stock a "buy" rating in a research note on Thursday. Wall Street Zen raised Revolution Medicines from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Truist Financial reissued a "buy" rating and issued a $261.00 target price (up from $241.00) on shares of Revolution Medicines in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $263.15.

Revolution Medicines Profile

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers.

The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.